These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Scintimammography: the new role of technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma. Khalkhali I; Iraniha S; Diggles LE; Cutrone JA; Mishkin FS Q J Nucl Med; 1997 Sep; 41(3):231-8. PubMed ID: 9274131 [TBL] [Abstract][Full Text] [Related]
11. Impact of patient positioning in scintimammography. Mirzaei S Eur J Nucl Med; 2001 Jul; 28(7):941-2. PubMed ID: 11504096 [No Abstract] [Full Text] [Related]
12. Sestamibi scanning of breast cancer. Shaffer P J Nucl Med; 2002 Jan; 43(1):125-6. PubMed ID: 11801715 [No Abstract] [Full Text] [Related]
13. Tc-99m sestamibi and Tc-99m HMDP uptake in a malignant phyllodes tumor of the breast. Ohta H; Yamamoto S; Ukikusa M; Awane H; Shintaku M; Irie K Clin Nucl Med; 1997 Aug; 22(8):553-4. PubMed ID: 9262903 [No Abstract] [Full Text] [Related]
14. Significant breast uptake of Tc-99m sestamibi in an actively lactating woman during SPECT myocardial perfusion imaging. Ramakrishna G; Miller TD J Nucl Cardiol; 2004; 11(2):222-3. PubMed ID: 15052253 [No Abstract] [Full Text] [Related]
15. Chemotherapy and uptake of technetium-99m sestamibi in breast cancer. Derebek E Eur J Nucl Med; 1998 Apr; 25(4):448. PubMed ID: 9643975 [No Abstract] [Full Text] [Related]
16. What can we expect from MDR breast cancer imaging with sestamibi? Palmedo H J Nucl Med; 2002 Apr; 43(4):526-30. PubMed ID: 11937597 [No Abstract] [Full Text] [Related]
17. [Complementary scintigraphic examinations (99mTc-MDP, 99mTc-MIBI and Octreoscan) in breast neoplasm assessment]. Stefănescu C; Chossiere L; Rusu V; Meignan M Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):165-8. PubMed ID: 9455458 [TBL] [Abstract][Full Text] [Related]
18. Differentiation between benign and malignant breast lesions with MR imaging and scintimammography. Servais F; Blocklet DC; Seret AE; Lenaers A; Schoutens AC Radiology; 1997 Oct; 205(1):283; author reply 285-6. PubMed ID: 9315001 [No Abstract] [Full Text] [Related]
19. A perspective on decision analysis modeling as it relates to sestamibi imaging of nonpalpable breast abnormalities. Waxman AD J Nucl Med; 1997 Nov; 38(11):1778-80. PubMed ID: 9374353 [No Abstract] [Full Text] [Related]
20. Differentiation between benign and malignant breast lesions with MR imaging and scintimammography. Delpassand ES; Jackson EF Radiology; 1997 Oct; 205(1):283-4; author reply 285-6. PubMed ID: 9315002 [No Abstract] [Full Text] [Related] [Next] [New Search]